Hyperlipidemia Drugs Market

Global Hyperlipidemia Drugs Market Size, Trends & Analysis - Forecasts to 2026 By Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Others), By End-User (Hospitals, Clinics, Others), By Region (North America, Europe, Asia Pacific, MEA, and CSA); End-User Landscape, Company Market Share Analysis & Competitor Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on May 9 2022 with the latest and most recent market numbers

Hyperlipidemia Drugs Market Insights

The hyperlipidemia drugs market is estimated to be valued at USD 21.84 Billion in 2021 and is projected to reach USD 24.71 Billion by 2026 at a CAGR of 2.5%. The key drivers which contribute to the market include the increased incidence of chronic disorders such as diabetes, heart diseases, and cancer, increasing unusual cholesterol levels, addiction to ready-to-eat products, and an upsurge in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels.

Moreover, continually changing lifestyles, irregular intake of weight gain eatables, unhealthy diets, smoking & drinking, ongoing technological developments, growing public awareness of nutraceuticals, increasing income levels, and rising government initiatives catalyze the overall growth.

The market is expanding at a rapid pace, attributable to an uptick in the target demographic and increased consciousness regarding the threat of cardiovascular disease (CVD) caused by persistent hypercholesterolemia. Furthermore, forthcoming patent expiration will lead to genericization in the market, most notably in statin drugs and lipid absorption antagonists, which will fuel the market to a degree. A myriad range of new drug releases is also foreseen to propel the market. ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3, for example, are being studied for their capability to cure hyperlipidemia and also reduce the threat of CVD.

One of the vital considerations driving the market's expansion is the rising preponderance of hyperlipidemia around the world. Moreover, the growing geriatric demographic, which is more vulnerable to high cholesterol levels and heart disease, is boosting market expansion.

In accordance with this, soaring health cognition amongst the general public, as well as increased understanding of the accessible therapeutic options for hypercholesterolemia, is favoring market advancement.

Assorted technological breakthroughs namely the creation of unique drug classes with improved efficacy are also functioning as growth inducers. Such drugs enhance endothelial function and the cohesion of atherosclerotic lesions while causing a minuscule inflammatory response and cellular damage. Other considerations, such as comprehensive R&D activities in the domain of biomedical sciences, as well as cumulative advancements in medical facilities around the world, are expected to drive the market even further.

Numerous different aspects, like generic drugs and financing accessibility, medical care centers implementing health education campaigns, the increasing incidence rate of heart disease, and increasing awareness about lowering cholesterol levels to regulate cardiovascular disease are likely to drive the market during the forecast period. A vast variety of hyperlipidemia medications are currently being evaluated in phase III clinical studies to see if they provide clinical benefits and have long-term safety records.

global hyperlipidemia drugs market

Hyperlipidemia Drugs Market: By Drug class

Based on drug class, the market is segmented into statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combinations, and others.

During the forecast period, the market for statins is estimated to predominate. This dominance can be attributed to an uptick in the predominance of CVD. Statins are the first-line therapeutic approach that minimizes the threat of heart attacks, which also corresponds to the market's expansion. Furthermore, rewards including optimized endothelial function, increased atherosclerotic plaque steadiness, and reduced inflammatory response and cellular damage caused by oxidative stress are responsible for statin preference and driving the market.

Others include miscellaneous antihyperlipidemic agents that entail niacin, omega-3 fatty acids, MTP-inhibitors, apoB-100 inhibitors, and more recent agents such as ACL-inhibitors. This segment is estimated to have lucrative growth due to fewer health risks, soaring adoption of these products, and improved efficacy. Moreover, a burgeoning proportion of the key players are collaborating to introduce new innovative products to strengthen their product portfolio and pipeline, which aids in the better treatment of CVD diseases.

Hyperlipidemia Drugs Market: By End-User

Based on end-user, the market is segmented into hospitals, clinics, and others. During the forecast period, the market for the hospital's segment is estimated to predominate. Patients at hospitals have complete access to exceptional competence, resources, and therapeutic programs that are not always useable at overall rehabilitation facilities. Hospitals frequently have extensive experience treating patients with a wide spectrum of diseases.

Globally, healthcare and diagnostic facilities are in burgeoning demand due to extensive studies on targeted therapies for terminal illnesses, which have benefited from advanced medical technology, and a growing populace of patients opting for early disease detection. Hospitals also have the provision of a comprehensive range of medications, types of equipment, and sophisticated technologies which aid in their predominance.

asia pacific hyperlipidemia drugs market

Hyperlipidemia Drugs Market: By Region

As per the geographical analysis, the market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central South America (Brazil, Argentina, and Rest of Central and South America).

Europe is presumed to retain a significant market share in the global market due to rising hypercholesterolemia preponderance, rising healthcare spending, and the involvement of well-established medical facilities. Furthermore, an increase in the overweight demographic in this area which will lead to the adoption of hyperlipidemia drugs for interventional purposes is foreseen to contribute to market development. Because of the increased preponderance of ailments affiliated with uplifted levels of lipoproteins and the burgeoning baby boomer demographic, Europe predominates.

According to the World Health Organization, 133 million people in the European Union's leading countries – Germany, France, Italy, Spain, and the United Kingdom – are affected by high cholesterol. Individuals with elevated levels of blood cholesterol have a higher risk of developing heart disease because plaque accumulates inside the coronary arteries. This is one of the prominent rationales for the supremacy of the European region in the global market.

Due to the thoroughly established healthcare system and elevated market penetration of technically sophisticated targeted therapies, Asia Pacific is expected to be a highly appealing region of the market during the forecast period. Furthermore, the aging demographic and increased knowledge and understanding of heart disease are two factors driving the market.

Hyperlipidemia Drugs Market Share and Competitor Analysis

Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi S.A. are the key players in the market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1   Methodology

1.1    Market Scope & Definitions

1.2    Estimates & Forecast Calculation

1.3    Historical Data Overview And Validation

1.4    Data Sources

1.4.1    Secondary

1.4.2    Primary

Chapter 2   Report Outlook

2.1    Hyperlipidemia Drugs Industry Overview, 2019-2026

2.1.1    Industry Overview

2.1.2    Drug Class Overview

2.1.3    End-User Overview

2.1.4    Regional Overview

Chapter 3   Hyperlipidemia Drugs Market Trends

3.1    Market Segmentation

3.2    Industry Background, 2019-2026

3.3    Market Key Trends

3.3.1    Positive Trends

3.3.1.1    Growth in Awareness About Risk of Cardiovascular Diseases

3.3.1.2    Emergence of Novel Drug Classes

3.3.1.3    Rise in Prevalence of Hyperlipidemia Across the Globe   

3.3.2    Market Restraints

3.3.2.1    Upcoming Patent Expirations of Drugs

3.3.2.2     Regulatory Framework

3.4    Prospective Growth Scenario

3.4.1    Drug Class Growth Scenario

3.4.2    End-User Growth Scenario

3.5    COVID-19 Influence over Industry Growth

3.6    Porter’s Analysis

3.7    PESTEL Analysis

3.8    Value Chain & Supply Chain Analysis

3.9    Regulatory Framework

3.9.1    North America

3.9.2    Europe

3.9.3    APAC

3.9.4    LATAM

3.9.5    MEA

3.10    Technology Overview

3.11    Market Share Analysis, 2020

3.11.1    Company Positioning Overview, 2020

Chapter 4   Hyperlipidemia Drugs Market, By Drug Class

4.1    Drug Class Outlook

4.2    Statins

4.2.1    Market Size, By Region, 2019-2026  (USD Billion)

4.3    PCSK9 Inhibitors

4.3.1    Market Size, By Region, 2019-2026  (USD Billion)

4.4    Bile Acid Sequestrants

4.4.1    Market Size, By Region, 2019-2026  (USD Billion)

4.5    Cholesterol Absorption Inhibitors

4.5.1    Market Size, By Region, 2019-2026  (USD Billion)

4.6    Fibric Acid Derivatives

4.6.1    Market Size, By Region, 2019-2026  (USD Billion)

4.7    Combination

4.7.1    Market Size, By Region, 2019-2026  (USD Billion)

4.3    Others

4.3.1    Market Size, By Region, 2019-2026  (USD Billion)

Chapter 5   Hyperlipidemia Drugs Market, By End-User

5.1    End-User Outlook

5.2    Hospitals

5.2.1    Market Size, By Region, 2019-2026  (USD Billion)

5.3    Clinics

5.3.1    Market Size, By Region, 2019-2026  (USD Billion)

5.4    Others

5.4.1    Market Size, By Region, 2019-2026  (USD Billion)

Chapter 6   Hyperlipidemia Drugs Market, By Region

6.1    Regional outlook

6.2    North America

6.2.1    Market Size, By Country 2019-2026  (USD Billion)

6.2.2    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.2.3    Market Size, By End-User, 2019-2026  (USD Billion)

6.2.4    U.S.

6.2.4.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.2.4.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.2.5    Canada

6.2.5.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.2.5.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.3    Europe

6.3.1    Market Size, By Country 2019-2026  (USD Billion)

6.3.2    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.3.3    Market Size, By End-User, 2019-2026  (USD Billion)

6.3.4    Germany

6.2.4.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.2.4.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.3.5    UK

6.3.5.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.3.5.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.3.6    France

6.3.6.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.3.6.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.3.7    Italy

6.3.7.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.3.7.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.3.8    Spain

6.3.8.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.3.8.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.3.9    Russia

6.3.9.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.3.9.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.4    Asia Pacific

6.4.1    Market Size, By Country 2019-2026  (USD Billion)

6.4.2    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.4.3    Market Size, By End-User, 2019-2026  (USD Billion)

6.4.4    China

6.4.4.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.4.4.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.4.5    India

6.4.5.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.4.5.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.4.6    Japan

6.4.6.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.4.6.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.4.7    Australia

6.4.7.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.4.7.2    Market size, By End-User, 2019-2026  (USD Billion)

6.4.8    South Korea

6.4.8.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.4.8.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.5    Latin America

6.5.1    Market Size, By Country 2019-2026  (USD Billion)

6.5.2    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.5.3    Market Size, By End-User, 2019-2026  (USD Billion)

6.5.4    Brazil

6.5.4.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.5.4.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.5.5    Mexico

6.5.5.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.5.5.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.5.6    Argentina

6.5.6.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.5.6.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.6    MEA

6.6.1    Market Size, By Country 2019-2026  (USD Billion)

6.6.2    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.6.3    Market Size, By End-User, 2019-2026  (USD Billion)

6.6.4    Saudi Arabia

6.6.4.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.6.4.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.6.5    UAE

6.6.5.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.6.5.2    Market Size, By End-User, 2019-2026  (USD Billion)

6.6.6    South Africa

6.6.6.1    Market Size, By Drug Class, 2019-2026  (USD Billion)

6.6.6.2    Market Size, By End-User, 2019-2026  (USD Billion)

Chapter 7   Company Landscape

7.1    Competitive Analysis, 2020

7.2    Amgen Inc

7.2.1    Company Overview

7.2.2    Financial Analysis

7.2.3    Strategic Positioning

7.2.4    Info Graphic Analysis

7.3    AstraZeneca PLC

7.3.1    Company Overview

7.3.2    Financial Analysis

7.3.3    Strategic Positioning

7.3.4    Info Graphic Analysis

7.4    Daiichi Sankyo Company Limited

7.4.1    Company Overview

7.4.2    Financial Analysis

7.4.3    Strategic Positioning

7.4.4    Info Graphic Analysis

7.5    Eli Lilly and Company

7.5.1    Company Overview

7.5.2    Financial Analysis

7.5.3    Strategic Positioning

7.5.4    Info Graphic Analysis

7.6    Esperion Therapeutics Inc

7.6.1    Company Overview

7.6.2    Financial Analysis

7.6.3    Strategic Positioning

7.6.4    Info Graphic Analysis

7.7     GlaxoSmithKline Pharmaceuticals Limited

7.7.1    Company Overview

7.7.2    Financial Analysis

7.7.3    Strategic Positioning

7.7.4    Info Graphic Analysis

7.8    Immuron Limited

7.8.1    Company Overview

7.8.2    Financial Analysis

7.8.3    Strategic Positioning

7.8.4    Info Graphic Analysis

7.9     Ionis Pharmaceuticals Inc

7.9.1    Company Overview

7.9.2    Financial Analysis

7.9.3    Strategic Positioning

7.9.4    Info Graphic Analysis

7.10    Merck & Co. Inc.

7.10.1    Company Overview

7.10.2    Financial Analysis

7.10.3    Strategic Positioning

7.10.4    Info Graphic Analysis

7.11    Pfizer Inc

7.11.1    Company Overview

7.11.2    Financial Analysis

7.11.3    Strategic Positioning

7.11.4    Info Graphic Analysis

7.12    Sanofi S.A

7.12.1    Company Overview

7.12.2    Financial Analysis

7.12.3    Strategic Positioning

7.12.4    Info Graphic Analysis

7.13    Other Companies

7.13.1    Company Overview

7.13.2    Financial Analysis

7.13.3    Strategic Positioning

7.13.4    Info Graphic Analysis

The Global Hyperlipidemia Drugs Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Hyperlipidemia Drugs Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy

Frequently Asked Questions

The global hyperlipidemia drugs market size is projected to grow from USD 21.84 billion in 2021 to USD 24.71 billion by 2026, at a CAGR of 2.5% during the forecast period.
Key and innovative vendors in the hyperlipidemia drugs market include Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi S.A.
Europe is estimated to hold the highest market share in the hyperlipidemia drugs market.
Globally, Covid-19 impact on the future hyperlipidemia drugs market will be quite significant for the manufacturers. Europe would be leading because of the increased preponderance of ailments affiliated with uplifted levels of lipoproteins. Subsequently, the Asia Pacific market will be growing the fastest because of the increased knowledge and understanding of heart disease.
The major driving factors for the hyperlipidemia drugs market include increased incidence of chronic disorders such as diabetes, heart diseases, and cancer; increasing unusual cholesterol levels; addiction to ready-to-eat products; an upsurge in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels; continually changing lifestyles; irregular intake of weight gain eatables; unhealthy diets; smoking & drinking; ongoing technological developments; growing public awareness of nutraceuticals; increasing income levels; rising government initiatives.

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius